The DOI matches its Crossref record; 56 of the 57 references it cites were found in a registry or an index.
Physical Fitness with Exercise and GLP-1 Receptor Agonist Treatment Alone or Combined After Diet-Induced Weight Loss: A Secondary Analysis of a Randomized Controlled Trial in Adults with Obesity
Open accessAbstract
Background: Obesity is associated with impaired physical fitness, including physical functional performance and cardiorespiratory fitness, which affect health-related quality of life and mortality. Objective: We aimed to investigate the efficacy of a moderate-to-vigorous intensity exercise program and glucagon-like peptide-1 receptor agonist treatment alone or in combination during weight maintenance for physical fitness. Methods: This is secondary analysis of a randomized controlled trial involving 193 adults with obesity (age 18–65 years, body mass index 32–43 kg/m 2 ) without diabetes mellitus who completed an 8-week low-calorie diet and were subsequently randomized (1:1:1:1 ratio) to: exercise plus placebo; glucagon-like peptide-1 receptor agonist liraglutide 3 mg once-daily plus usual activity; exercise plus liraglutide combined; or placebo plus usual activity. The exercise program was a combination of group sessions (interval-based indoor cycling followed by circuit training) and individual sessions of moderate-to-vigorous intensity, designed to meet the World Health Organization recommendations on physical activity for health. Exercise adherence was measured with sports watches and heart rate monitors. Key secondary endpoints related to physical fitness were changes from randomization to the end of treatment (weeks 0–52) in: (1) physical functional performance (time to ascend and descend an 11-step stairway twice); (2) cardiorespiratory fitness (peak oxygen consumption normalized to fat-free mass); and (3) muscle strength (isometric knee extensor peak torque). Results: Participants randomized to exercise performed a median 2.65 session/week (116 min/week at 79% of maximum heart rate) with no significant difference between those who received placebo or liraglutide. Compared with liraglutide alone, the combined treatment decreased time to complete a stair climb test by 1.2 s [95% confidence interval 0.6–1.9] (corresponding to 8.6%) and improved peak oxygen consumption by 3.0 mL/min/kg fat-free mass [95% confidence interval 0.5–5.5]. Exercise alone led to similar benefits, whereas liraglutide alone did not improve physical fitness. Compared with placebo (− 7.8%), relative muscle strength (strength normalized to body weight) was higher with exercise (− 0.4%), liraglutide (+ 1.0%), and the combined treatment (+ 3.3%) because of lower weight and preserved absolute strength. Conclusions: Structured exercise combined with glucagon-like peptide-1-based obesity pharmacotherapy led to clinically meaningful improvements in physical functional performance and cardiorespiratory fitness, in contrast to pharmacotherapy alone. Clinical Trial Registration: EudraCT number, 2015-005585-32; ClinicalTrials.gov number, NCT04122716.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“physical performance and functional outcomes are generally preserved or improved in most studies, particularly when resistance training is maintained”
From Weight maintenance after discontinuation of GLP-1 therapies (2026) · cites this paper as [72]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing
Benjamini, Y., & Hochberg, Y. (1995) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1995.tb02031.x · Cited by 109,482 · cited 1×
“The Benjamini–Hochberg procedure [35] was used to control the false discovery rate (5%).”
World Health Organization 2020 guidelines on physical activity and sedentary behaviour
Bull, F. C., Al-Ansari, S. S., Biddle, S., Borodulin, K., Buman, M. P., Cardon, G., Carty, C., Chaput, J.-P., Chastin, S., Chou, R., et al. (2020) · British Journal of Sports Medicine · doi:10.1136/bjsports-2020-102955 · Cited by 11,657 · cited 1×
“…program included a 6-week ramp-up phase, and from weeks 7 to 52, the aim was to follow the World Health Organization’s recommendations on physical activity for health, i.e., at least 150 min/week of moderate intensity, 75 min/week of vigorous intensity, or an equivalent combination of both [31].”
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205 · cited 1×
“The phase III trials of liraglutide, semaglutide, and tirzepatide all showed improvements in self-reported physical functioning [14, 43, 44].”
Tirzepatide Once Weekly for the Treatment of Obesity
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206038 · Cited by 3,838 · cited 1×
“The phase III trials of liraglutide, semaglutide, and tirzepatide all showed improvements in self-reported physical functioning [14, 43, 44].”
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724 · cited 2×
“The phase III trials of liraglutide, semaglutide, and tirzepatide all showed improvements in self-reported physical functioning [14, 43, 44].”
DONNELLY, J. E., BLAIR, S. N., JAKICIC, J. M., MANORE, M. M., RANKIN, J. W., & SMITH, B. K. (2009) · Medicine & Science in Sports & Exercise · doi:10.1249/mss.0b013e3181949333 · Cited by 2,658
Ross, R., Blair, S. N., Arena, R., Church, T. S., Després, J.-P., Franklin, B. A., Haskell, W. L., Kaminsky, L. A., Levine, B. D., Lavie, C. J., et al. (2016) · Circulation · doi:10.1161/cir.0000000000000461 · Cited by 2,486 · cited 3×
“…with reduced all-cause and cardiovascular mortality and prevention of age-related declines [2, 33, 34] and were considered realistic to detect [7, 26], and they were therefore chosen as the minimum clinically relevant differences (see the statistical analysis plan in the ESM for details).”
Limiting factors for maximum oxygen uptake and determinants of endurance performance
BASSETT, D. R. (2000) · Medicine & Science in Sports & Exercise · doi:10.1097/00005768-200001000-00012 · Cited by 2,410 · cited 1×
“As liraglutide alone did not improve cardiorespiratory fitness compared with placebo, we speculate that the improvements observed with combined exercise and liraglutide were mainly due to exercise-induced physiological adaptations [51], rather than weight loss per se.”
Balady, G. J., Arena, R., Sietsema, K., Myers, J., Coke, L., Fletcher, G. F., Forman, D., Franklin, B., Guazzi, M., Gulati, M., et al. (2010) · Circulation · doi:10.1161/cir.0b013e3181e52e69 · Cited by 1,964
Newman, A. B., Kupelian, V., Visser, M., Simonsick, E. M., Goodpaster, B. H., Kritchevsky, S. B., Tylavsky, F. A., Rubin, S. M., Harris, T. B., & on Behalf of the Health, A. A. B. C. S. I. (2006) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/61.1.72 · Cited by 1,692 · cited 1×
“Nevertheless, muscle strength is more strongly associated with adverse outcomes and mortality than muscle mass [24].”
Cited by
Weight maintenance after discontinuation of GLP-1 therapies
Moiz, A., Filion, K. B., Knäuper, B., Tsoukas, M. A., Brazeau, A.-S., Zolotarova, T., Lelièvre, A., & Eisenberg, M. J. (2026) · EClinicalMedicine · doi:10.1016/j.eclinm.2026.103992 · Cited by 7
“71,72 Beyond its role in preserving strength and function, skeletal muscle plays a central role in metabolic regulation.”
Sancho-Haro, E. S., Muñoz-López, M., Baz-Valle, E., Villanueva-Tobaldo, C. V., Tornero-Aguilera, J. F., López-Gil, J. F., López‐Moreno, M., Martín-Rodríguez, A., & Clemente‐Suárez, V. J. (2026) · Pharmaceuticals · doi:10.3390/ph19060897 · Cited by 2
Olumuyide, E. O., Ariel, K., & Aneni, E. (2026) · International Journal of Obesity · doi:10.1038/s41366-026-02143-x · Cited by 1
Ming, Q., & Li, Z. (2026) · Frontiers in Nutrition · doi:10.3389/fnut.2026.1914155
Damasio, N. M. A., Freccia, G. W., Fortes, M. D. S. R., Gomes, M. G. Z., & de Lira, C. A. B. (2026) · Obesity Medicine · doi:10.1016/j.obmed.2026.100743
Metadata
- Authors
- Jensen, S. B. K., Fiorenza, M., Juhl, C. R., Sandsdal, R. M., Jensen, E., Seier, S. S., Janus, C., Jørgensen, J. R., Blond, M. B., Holst, J. J., Stallknecht, B. M., Madsbad, S., Bandholm, T., & Torekov, S. S.
- Affiliations
- University of Copenhagen (DK)
- Steno Diabetes Center Copenhagen (DK)
- Corresponding author
- Jensen, Simon Birk Kjær
- Torekov, Signe Sørensen
- ORCID
- Venue
- Sports Medicine
- Published
- 2026-01-24
- Volume
- 56
- Issue
- 7
- Pages
- 1785-1800
- ISSN
- 0112-1642 (ISSN-L)
- 1179-2035
- PMC
- PMC13388483
- OpenAlex
- W7125578635
- Cited by
- 9
- References
- 57
- Citations by year
- 2026: 9
- FWCI
- 41.14
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Sports Medicine (publishedVersion, cc-by)
- PubMed (publishedVersion)
- PubMed Central (publishedVersion, cc-by)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion, cc-by)
- Funders
- Novo Nordisk Fonden (NNF16OC0019968, NNF15CC0018486)
- Helsefonden
- Novo Nordisk Foundation Center for Basic Metabolic Research
- Danish Diabetes and Endocrine Academy
- Danish Cardiovascular Academy
- Det Sundhedsvidenskabelige Fakultet, Københavns Universitet
- Copenhagen University
- Topics
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Physical Activity and Health
- Health Sciences › Medicine › Physiology (medical) › Cardiovascular and exercise physiology
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Keywords
- obesity, physical fitness, physical activity, liraglutide, GLP-1 receptor agonists, weight maintenance, hypocaloric diet, cardiorespiratory fitness, peak oxygen uptake, physical functional performance, muscle strength, quadriceps strength, weight loss, exercise adherence, circuit training, health-related quality of life
- MeSH terms
- Liraglutide, Cardiorespiratory Fitness, Glucagon-Like Peptide-1 Receptor Agonists, Adolescent, Adult, Aged, Combined Modality Therapy, Diet, Reducing, Exercise Therapy, Female, Humans, Hypoglycemic Agents, Male, Middle Aged, Obesity, Physical Fitness, Weight Loss, Caloric Restriction, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Physical Fitness with Exercise and GLP-1 Receptor Agonist Treatment Alone or Combined After Diet-Induced Weight Loss: A Secondary Analysis of a Randomized Controlled Trial in Adults with Obesity. https://app.cochat.ai/papers/10.1007/s40279-025-02386-0
- The paper
- Jensen, S. B. K., Fiorenza, M., Juhl, C. R., Sandsdal, R. M., Jensen, E., Seier, S. S., Janus, C., Jørgensen, J. R., Blond, M. B., Holst, J. J., Stallknecht, B. M., Madsbad, S., Bandholm, T., & Torekov, S. S. (2026). Physical Fitness with Exercise and GLP-1 Receptor Agonist Treatment Alone or Combined After Diet-Induced Weight Loss: A Secondary Analysis of a Randomized Controlled Trial in Adults with Obesity. Sports Medicine. https://doi.org/10.1007/s40279-025-02386-0
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.